Biotech Values

[justrpaul]

When the ABBVIE/ESRX deal was announced last December, ESRX said they would now treat all HCV sufferers regardless of disease severity. If we use an average commercial prevalence rate, ESRX's 25 million member national plan has about 125,000 members with HCV, of those maybe 88,000 are GT1. Given the continuing small viekira numbers, one has to doubt the ESRX promise of treating everyone without regard to disease severity.